Top

Published in:

25-04-2024 | ESCAP Communication

ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines

Authors: Samuele Cortese, David Coghill, Joerg M. Fegert, Gregory W. Mattingly, Luis A. Rohde, Ian C.K. Wong, Stephen V. Faraone

Published in: European Child & Adolescent Psychiatry | Issue 5/2024

Excerpt

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, affecting around 5% of school age children and at least 2.5% of adults worldwide. ADHD is often comorbid with other conditions, including mood, anxiety, and substance use disorders. If untreated, ADHD increases the risk of a series of negative outcomes, such as impaired school, emotional, and social functioning, lower quality of life, as well as increased risk of accidental injuries, substance misuse, criminal acts, premature death, and suicide [1]. …

Faraone SV, Banaschewski T, Coghill D et al (2021) The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev 128:789–818CrossRefPubMedPubMedCentral

Dodds M, Arachchige Done SW, Gold L, oghill D, Le HND (2024) Economic burden and service utilization of children with Attention-Deficit/Hyperactivity disorder: a systematic review and Meta-analysis. Value Health 27(2):247–264CrossRefPubMed

Sciberras E, Streatfeild J, Ceccato T et al (2022) Social and economic costs of Attention-Deficit/Hyperactivity disorder across the Lifespan. J Atten Disord 26(1):72–87CrossRefPubMed

Cortese S (2020) Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med 383(11):1050–1056CrossRefPubMed

Leucht S, Hierl S, Kissling W, Dold M, Favis JM (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200(2):97–106CrossRefPubMed

Chen VC, Chan H-L, Wu SI et al (2020) Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study. Br J Psychiatry 1–9

Lin LZ, Chang L, Kuja-Halkola et al (2024) ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA 331(10):850–860

Vasiliadis HL, Rahme E, Rochette L et al (2024) ADHD medications use and risk of mortality and unintentional injuries: a population-based cohort study. Transl Psychiatry 14(1):128

Man KKC, hage A, Banaschewski T et al (2023) Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the attention deficit hyperactivity disorder drugs use Chronic effects (ADDUCE) study. Lancet Psychiatry 10(5):323–333CrossRefPubMed

10.

Buitelaar JK, van de Loo-Neus J, Hennissen L et al (2022) Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 64:63–71CrossRefPubMed

11.

Zhang L, Li L, Andell P et al (2024) Attention-Deficit/Hyperactivity Disorder Medications and long-term risk of Cardiovascular diseases. JAMA Psychiatry 81(2):178–187CrossRefPubMed

12.

Banaschewski T, Buitelaar J, Chui CS et al (2016) Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. Evid Based Ment Health 19(4):97–99CrossRefPubMedPubMedCentral

13.

Cipriani A, Furukawa T, Salanti G et al (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366CrossRefPubMedPubMedCentral

14.

Cortese S, Coghill D, Mattingly GW et al (2013) WHO model lists of essential Medicines: methylphenidate for ADHD in children and adolescents. Lancet Psychiatry 10(10):743–744CrossRef

Title: ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines
Authors: Samuele Cortese
David Coghill
Joerg M. Fegert
Gregory W. Mattingly
Luis A. Rohde
Ian C.K. Wong
Stephen V. Faraone
Publication date: 25-04-2024
Publisher: Springer Berlin Heidelberg
Published in: European Child & Adolescent Psychiatry / Issue 5/2024
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-024-02443-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2024

Short-term effects of an elimination diet and healthy diet in children with attention-deficit/hyperactivity disorder: a randomized-controlled trial

Correction to: Does behavioural parent training reduce internalising symptoms (or not) among children with externalising problems? Systematic review and meta-analysis

ADHD-related sex differences in emotional symptoms across development

Correction to: Understanding the relationship between gender and mental health in adolescence: the Gender Adherence Index (GAI)

Drug-related catatonia in youths: real-world insights from the WHO Safety Database

Barriers and facilitators to social prescribing in child and youth mental health: perspectives from the frontline